Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival.

Oser MG, Fonseca R, Chakraborty AA, Brough R, Spektor A, Jennings RB, Flaifel A, Novak JS, Gulati A, Buss E, Younger ST, McBrayer SK, Cowley GS, Bonal DM, Nguyen QD, Brulle-Soumare L, Taylor P, Cairo S, Ryan CJ, Pease EJ, Maratea K, Travers J, Root DE, Signoretti S, Pellman D, Ashton S, Lord CJ, Barry ST, Kaelin WG Jr.

Cancer Discov. 2019 Feb;9(2):230-247. doi: 10.1158/2159-8290.CD-18-0389. Epub 2018 Oct 29.

2.

Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A.

PLoS One. 2018 Oct 26;13(10):e0206729. doi: 10.1371/journal.pone.0206729. eCollection 2018.

3.

Post-prostatectomy Lymphocoele Presenting With Renal Failure.

Sihra N, Kujawa M, Counsell A, Brough R.

Urology. 2019 Jan;123:e9-e10. doi: 10.1016/j.urology.2018.09.023. Epub 2018 Oct 9.

PMID:
30308260
4.

BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004).

Kelly JD, Tan WS, Porta N, Mostafid H, Huddart R, Protheroe A, Bogle R, Blazeby J, Palmer A, Cresswell J, Johnson M, Brough R, Madaan S, Andrews S, Cruickshank C, Burnett S, Maynard L, Hall E; BOXIT Investigators.

Eur Urol. 2019 Apr;75(4):593-601. doi: 10.1016/j.eururo.2018.09.020. Epub 2018 Sep 29.

PMID:
30279015
5.

Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.

Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ.

Sci Rep. 2018 Aug 21;8(1):12771. doi: 10.1038/s41598-018-30922-8.

6.

The shieldin complex mediates 53BP1-dependent DNA repair.

Noordermeer SM, Adam S, Setiaputra D, Barazas M, Pettitt SJ, Ling AK, Olivieri M, Álvarez-Quilón A, Moatti N, Zimmermann M, Annunziato S, Krastev DB, Song F, Brandsma I, Frankum J, Brough R, Sherker A, Landry S, Szilard RK, Munro MM, McEwan A, Goullet de Rugy T, Lin ZY, Hart T, Moffat J, Gingras AC, Martin A, van Attikum H, Jonkers J, Lord CJ, Rottenberg S, Durocher D.

Nature. 2018 Aug;560(7716):117-121. doi: 10.1038/s41586-018-0340-7. Epub 2018 Jul 18.

7.

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.

Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ.

Sci Rep. 2018 Jul 13;8(1):10614. doi: 10.1038/s41598-018-29043-z. Erratum in: Sci Rep. 2018 Aug 21;8(1):12771.

8.

Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer.

Brough R, Gulati A, Haider S, Kumar R, Campbell J, Knudsen E, Pettitt SJ, Ryan CJ, Lord CJ.

Oncogene. 2018 Oct;37(43):5701-5718. doi: 10.1038/s41388-018-0368-z. Epub 2018 Jun 18.

9.

The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells.

Barazas M, Annunziato S, Pettitt SJ, de Krijger I, Ghezraoui H, Roobol SJ, Lutz C, Frankum J, Song FF, Brough R, Evers B, Gogola E, Bhin J, van de Ven M, van Gent DC, Jacobs JJL, Chapman R, Lord CJ, Jonkers J, Rottenberg S.

Cell Rep. 2018 May 15;23(7):2107-2118. doi: 10.1016/j.celrep.2018.04.046.

10.

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.

Pettitt SJ, Krastev DB, Brandsma I, Dréan A, Song F, Aleksandrov R, Harrell MI, Menon M, Brough R, Campbell J, Frankum J, Ranes M, Pemberton HN, Rafiq R, Fenwick K, Swain A, Guettler S, Lee JM, Swisher EM, Stoynov S, Yusa K, Ashworth A, Lord CJ.

Nat Commun. 2018 May 10;9(1):1849. doi: 10.1038/s41467-018-03917-2.

11.

E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.

Bajrami I, Marlow R, van de Ven M, Brough R, Pemberton HN, Frankum J, Song F, Rafiq R, Konde A, Krastev DB, Menon M, Campbell J, Gulati A, Kumar R, Pettitt SJ, Gurden MD, Cardenosa ML, Chong I, Gazinska P, Wallberg F, Sawyer EJ, Martin LA, Dowsett M, Linardopoulos S, Natrajan R, Ryan CJ, Derksen PWB, Jonkers J, Tutt ANJ, Ashworth A, Lord CJ.

Cancer Discov. 2018 Apr;8(4):498-515. doi: 10.1158/2159-8290.CD-17-0603.

12.

Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer.

Witkiewicz AK, Chung S, Brough R, Vail P, Franco J, Lord CJ, Knudsen ES.

Cell Rep. 2018 Jan 30;22(5):1185-1199. doi: 10.1016/j.celrep.2018.01.022.

13.

ATR Is a Therapeutic Target in Synovial Sarcoma.

Jones SE, Fleuren EDG, Frankum J, Konde A, Williamson CT, Krastev DB, Pemberton HN, Campbell J, Gulati A, Elliott R, Menon M, Selfe JL, Brough R, Pettitt SJ, Niedzwiedz W, van der Graaf WTA, Shipley J, Ashworth A, Lord CJ.

Cancer Res. 2017 Dec 15;77(24):7014-7026. doi: 10.1158/0008-5472.CAN-17-2056. Epub 2017 Oct 16.

14.

Modeling Therapy Resistance in BRCA1/2-Mutant Cancers.

Dréan A, Williamson CT, Brough R, Brandsma I, Menon M, Konde A, Garcia-Murillas I, Pemberton HN, Frankum J, Rafiq R, Badham N, Campbell J, Gulati A, Turner NC, Pettitt SJ, Ashworth A, Lord CJ.

Mol Cancer Ther. 2017 Sep;16(9):2022-2034. doi: 10.1158/1535-7163.MCT-17-0098. Epub 2017 Jun 15.

15.

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A.

PLoS One. 2017 Apr 20;12(4):e0176578. doi: 10.1371/journal.pone.0176578. eCollection 2017. Erratum in: PLoS One. 2018 Oct 26;13(10):e0206729.

16.

De Novo Truncating Mutations in the Last and Penultimate Exons of PPM1D Cause an Intellectual Disability Syndrome.

Jansen S, Geuer S, Pfundt R, Brough R, Ghongane P, Herkert JC, Marco EJ, Willemsen MH, Kleefstra T, Hannibal M, Shieh JT, Lynch SA, Flinter F, FitzPatrick DR, Gardham A, Bernhard B, Ragge N, Newbury-Ecob R, Bernier R, Kvarnung M, Magnusson EA, Wessels MW, van Slegtenhorst MA, Monaghan KG, de Vries P, Veltman JA; Deciphering Developmental Disorders Study, Lord CJ, Vissers LE, de Vries BB.

Am J Hum Genet. 2017 Apr 6;100(4):650-658. doi: 10.1016/j.ajhg.2017.02.005. Epub 2017 Mar 23.

17.

Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells.

Pettitt SJ, Krastev DB, Pemberton HN, Fontebasso Y, Frankum J, Rehman FL, Brough R, Song F, Bajrami I, Rafiq R, Wallberg F, Kozarewa I, Fenwick K, Armisen-Garrido J, Swain A, Gulati A, Campbell J, Ashworth A, Lord CJ.

Sci Data. 2017 Mar 1;4:170020. doi: 10.1038/sdata.2017.20.

18.

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.

Williamson CT, Miller R, Pemberton HN, Jones SE, Campbell J, Konde A, Badham N, Rafiq R, Brough R, Gulati A, Ryan CJ, Francis J, Vermulen PB, Reynolds AR, Reaper PM, Pollard JR, Ashworth A, Lord CJ.

Nat Commun. 2016 Dec 13;7:13837. doi: 10.1038/ncomms13837.

19.

The future of financing for HIV services in Uganda and the wider sub-Saharan Africa region: should we ask patients to contribute to the cost of their care?

Kakaire T, Schlech W, Coutinho A, Brough R, Parkes-Ratanshi R.

BMC Public Health. 2016 Aug 27;16:896. doi: 10.1186/s12889-016-3573-0.

20.

Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.

Miller RE, Brough R, Bajrami I, Williamson CT, McDade S, Campbell J, Kigozi A, Rafiq R, Pemberton H, Natrajan R, Joel J, Astley H, Mahoney C, Moore JD, Torrance C, Gordan JD, Webber JT, Levin RS, Shokat KM, Bandyopadhyay S, Lord CJ, Ashworth A.

Mol Cancer Ther. 2016 Jul;15(7):1472-84. doi: 10.1158/1535-7163.MCT-15-0554. Epub 2016 Jun 30.

21.

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A.

PLoS One. 2016 Apr 18;11(4):e0154007. doi: 10.1371/journal.pone.0154007. eCollection 2016. No abstract available.

22.

Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines.

Campbell J, Ryan CJ, Brough R, Bajrami I, Pemberton HN, Chong IY, Costa-Cabral S, Frankum J, Gulati A, Holme H, Miller R, Postel-Vinay S, Rafiq R, Wei W, Williamson CT, Quigley DA, Tym J, Al-Lazikani B, Fenton T, Natrajan R, Strauss SJ, Ashworth A, Lord CJ.

Cell Rep. 2016 Mar 15;14(10):2490-501. doi: 10.1016/j.celrep.2016.02.023. Epub 2016 Mar 3.

23.

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A.

PLoS One. 2016 Feb 16;11(2):e0149099. doi: 10.1371/journal.pone.0149099. eCollection 2016. Erratum in: PLoS One. 2016;11(4):e0154007. PLoS One. 2017 Apr 20;12 (4):e0176578.

24.

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A'Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, de Bono JS.

N Engl J Med. 2015 Oct 29;373(18):1697-708. doi: 10.1056/NEJMoa1506859.

25.

Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.

Kwon YJ, Petrie K, Leibovitch BA, Zeng L, Mezei M, Howell L, Gil V, Christova R, Bansal N, Yang S, Sharma R, Ariztia EV, Frankum J, Brough R, Sbirkov Y, Ashworth A, Lord CJ, Zelent A, Farias E, Zhou MM, Waxman S.

Mol Cancer Ther. 2015 Aug;14(8):1824-36. doi: 10.1158/1535-7163.MCT-14-0980-T. Epub 2015 Jun 15.

26.

Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.

Frankum J, Moudry P, Brough R, Hodny Z, Ashworth A, Bartek J, Lord CJ.

Oncotarget. 2015 May 10;6(13):10746-58.

27.

Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways.

Aarts M, Bajrami I, Herrera-Abreu MT, Elliott R, Brough R, Ashworth A, Lord CJ, Turner NC.

Mol Cancer Ther. 2015 Apr;14(4):865-76. doi: 10.1158/1535-7163.MCT-14-0845. Epub 2015 Feb 11.

28.

Embryology and adult urology - Not always mutually exclusive: A case report on true hermaphroditism at an adult urology clinic.

Turo R, Derbyshire LF, Smolski M, Collins GN, Lynch N, Lewinski M, Brough RJ, Sinclair AM.

Can Urol Assoc J. 2014 Sep;8(9-10):E650-3. doi: 10.5489/cuaj.2035.

29.

A rare case of testicular metastasis of bladder transitional cell carcinoma.

Turo R, Smolski M, Hatimy U, Bromage SJ, Brown SC, Brough R, Collins GN.

Can Urol Assoc J. 2014 Mar-Apr;8(3-4):E181-3. doi: 10.5489/cuaj.1690.

30.

Acute urinary retention in women due to urethral calculi: A rare case.

Turo R, Smolski M, Kujawa M, Brown SC, Brough R, Collins GN.

Can Urol Assoc J. 2014 Jan-Feb;8(1-2):E99-E100. doi: 10.5489/cuaj.1573.

31.

Diethylstilboestrol for the treatment of prostate cancer: past, present and future.

Turo R, Smolski M, Esler R, Kujawa ML, Bromage SJ, Oakley N, Adeyoju A, Brown SC, Brough R, Sinclair A, Collins GN.

Scand J Urol. 2014 Feb;48(1):4-14. doi: 10.3109/21681805.2013.861508. Epub 2013 Nov 21. Review.

PMID:
24256023
32.

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.

Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S, Chen L, Kozarewa I, Assiotis I, Fenwick K, Natrajan R, Lord CJ, Ashworth A.

Cancer Res. 2014 Jan 1;74(1):287-97. doi: 10.1158/0008-5472.CAN-13-2541. Epub 2013 Nov 15.

33.

Bladder neck sparing in radical prostatectomy.

Smolski M, Esler RC, Turo R, Collins GN, Oakley N, Brough R.

Indian J Urol. 2013 Oct;29(4):338-44. doi: 10.4103/0970-1591.120118.

34.

A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity.

Pettitt SJ, Rehman FL, Bajrami I, Brough R, Wallberg F, Kozarewa I, Fenwick K, Assiotis I, Chen L, Campbell J, Lord CJ, Ashworth A.

PLoS One. 2013 Apr 25;8(4):e61520. doi: 10.1371/journal.pone.0061520. Print 2013.

35.

Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies.

Shiu KK, Wetterskog D, Mackay A, Natrajan R, Lambros M, Sims D, Bajrami I, Brough R, Frankum J, Sharpe R, Marchio C, Horlings H, Reyal F, van der Vijver M, Turner N, Reis-Filho JS, Lord CJ, Ashworth A.

Oncogene. 2014 Jan 30;33(5):619-31. doi: 10.1038/onc.2012.625. Epub 2013 Jan 21.

36.

Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer.

Ruark E, Snape K, Humburg P, Loveday C, Bajrami I, Brough R, Rodrigues DN, Renwick A, Seal S, Ramsay E, Duarte Sdel V, Rivas MA, Warren-Perry M, Zachariou A, Campion-Flora A, Hanks S, Murray A, Ansari Pour N, Douglas J, Gregory L, Rimmer A, Walker NM, Yang TP, Adlard JW, Barwell J, Berg J, Brady AF, Brewer C, Brice G, Chapman C, Cook J, Davidson R, Donaldson A, Douglas F, Eccles D, Evans DG, Greenhalgh L, Henderson A, Izatt L, Kumar A, Lalloo F, Miedzybrodzka Z, Morrison PJ, Paterson J, Porteous M, Rogers MT, Shanley S, Walker L, Gore M, Houlston R, Brown MA, Caufield MJ, Deloukas P, McCarthy MI, Todd JA; Breast and Ovarian Cancer Susceptibility Collaboration; Wellcome Trust Case Control Consortium, Turnbull C, Reis-Filho JS, Ashworth A, Antoniou AC, Lord CJ, Donnelly P, Rahman N.

Nature. 2013 Jan 17;493(7432):406-10. doi: 10.1038/nature11725. Epub 2012 Dec 16.

37.

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells.

Bajrami I, Kigozi A, Van Weverwijk A, Brough R, Frankum J, Lord CJ, Ashworth A.

EMBO Mol Med. 2012 Oct;4(10):1087-96. doi: 10.1002/emmm.201201250. Epub 2012 Aug 30.

38.

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.

Daemen A, Wolf DM, Korkola JE, Griffith OL, Frankum JR, Brough R, Jakkula LR, Wang NJ, Natrajan R, Reis-Filho JS, Lord CJ, Ashworth A, Spellman PT, Gray JW, van't Veer LJ.

Breast Cancer Res Treat. 2012 Sep;135(2):505-17. doi: 10.1007/s10549-012-2188-0. Epub 2012 Aug 9.

39.

Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers.

Stratford AL, Reipas K, Hu K, Fotovati A, Brough R, Frankum J, Takhar M, Watson P, Ashworth A, Lord CJ, Lasham A, Print CG, Dunn SE.

Stem Cells. 2012 Jul;30(7):1338-48. doi: 10.1002/stem.1128.

40.

APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer.

Brough R, Bajrami I, Vatcheva R, Natrajan R, Reis-Filho JS, Lord CJ, Ashworth A.

EMBO J. 2012 Mar 7;31(5):1160-76. doi: 10.1038/emboj.2011.490. Epub 2012 Jan 31.

41.

Functional characterization of protein variants of the human multidrug transporter ABCC2 by a novel targeted expression system in fibrosarcoma cells.

Arlanov R, Porter A, Strand D, Brough R, Karpova D, Kerb R, Wojnowski L, Schwab M, Lang T.

Hum Mutat. 2012 Apr;33(4):750-62. doi: 10.1002/humu.22041. Epub 2012 Feb 28.

PMID:
22290738
42.

Developing independent investigators for clinical research relevant for Africa.

Manabe YC, Katabira E, Brough RL, Coutinho AG, Sewankambo N, Merry C.

Health Res Policy Syst. 2011 Dec 29;9:44. doi: 10.1186/1478-4505-9-44.

43.

Functional viability profiles of breast cancer.

Brough R, Frankum JR, Sims D, Mackay A, Mendes-Pereira AM, Bajrami I, Costa-Cabral S, Rafiq R, Ahmad AS, Cerone MA, Natrajan R, Sharpe R, Shiu KK, Wetterskog D, Dedes KJ, Lambros MB, Rawjee T, Linardopoulos S, Reis-Filho JS, Turner NC, Lord CJ, Ashworth A.

Cancer Discov. 2011 Aug;1(3):260-73. doi: 10.1158/2159-8290.CD-11-0107. Epub 2011 Aug 2.

44.

Searching for synthetic lethality in cancer.

Brough R, Frankum JR, Costa-Cabral S, Lord CJ, Ashworth A.

Curr Opin Genet Dev. 2011 Feb;21(1):34-41. doi: 10.1016/j.gde.2010.10.009. Epub 2011 Jan 20. Review.

PMID:
21255997
45.

Early prostate cancer--which treatment do men prefer and why?

Anandadas CN, Clarke NW, Davidson SE, O'Reilly PH, Logue JP, Gilmore L, Swindell R, Brough RJ, Wemyss-Holden GD, Lau MW, Javle PM, Ramani VA, Wylie JP, Collins GN, Brown S, Cowan RA; North West Uro-oncology Group.

BJU Int. 2011 Jun;107(11):1762-8. doi: 10.1111/j.1464-410X.2010.09833.x. Epub 2010 Nov 17.

46.

Diagnostic dilemmas in substance disorders.

Brough R.

Aust Fam Physician. 2010 Aug;39(8):536-7.

47.

Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation.

de Plater L, Laugé A, Guyader C, Poupon MF, Assayag F, de Cremoux P, Vincent-Salomon A, Stoppa-Lyonnet D, Sigal-Zafrani B, Fontaine JJ, Brough R, Lord CJ, Ashworth A, Cottu P, Decaudin D, Marangoni E.

Br J Cancer. 2010 Oct 12;103(8):1192-200. doi: 10.1038/sj.bjc.6605900. Epub 2010 Sep 28.

48.

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.

Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, Waldman T, Lord CJ, Ashworth A.

EMBO Mol Med. 2009 Sep;1(6-7):315-22. doi: 10.1002/emmm.200900041.

49.

The '2-week wait' rule for referrals for suspected urological cancers--urgent need for refinement of criteria.

Hawary AM, Warburton HE, Brough RJ, Collins GN, Brown SC, O'Reilly PH, Adeyoju AA.

Ann R Coll Surg Engl. 2008 Sep;90(6):517-22. doi: 10.1308/003588408X301082.

50.

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor.

Turner NC, Lord CJ, Iorns E, Brough R, Swift S, Elliott R, Rayter S, Tutt AN, Ashworth A.

EMBO J. 2008 May 7;27(9):1368-77. doi: 10.1038/emboj.2008.61. Epub 2008 Apr 3.

Supplemental Content

Loading ...
Support Center